Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 19 tags : Pharm-country save search
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
Published: 2022-04-19 (Crawled : 14:00) - biospace.com/
ECOR | $5.67 3.5K
|
Health Technology
|
| O: -0.77%
H: 3.74%
C: 0.8%
solutions defense biotech program
Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022
Published: 2022-04-19 (Crawled : 14:00) - biospace.com/
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: -0.38%
H: 2.95%
C: 0.26%
pharma
Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TV
Published: 2022-04-19 (Crawled : 14:00) - biospace.com/
ENZ | $1.16 35K
|
Health Technology
|
| O: 1.4%
H: 1.73%
C: 0.0%
covid-19 genflex test diagnostic health state hpv approval molecular
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
Published: 2022-04-19 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 -2.04% 39K
|
Health Technology
|
| O: -0.31%
H: 2.48%
C: 1.55%
brexafemme insurance
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-04-19 (Crawled : 12:00) - biospace.com/
ATNM | $8.0 -5.21% 170K
|
Health Technology
|
| O: 0.9%
H: 11.33%
C: 5.07%
trial therapy phase 3
Soligenix Receives $1.4M in Non-Dilutive Government Funding
Published: 2022-04-19 (Crawled : 12:00) - biospace.com/
SNGX | $0.54 39.86% 7.3M
|
Health Technology
|
| O: 0.47%
H: 0.04%
C: -1.22%
funding
Johnson & Johnson Announces Dividend Increase of 6.6%
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
Johnson & Johnson Reports Q1 2022 Results
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
results
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.